Hoth announces results from pilot study of BioLexa platform application
Hoth Therapeutics announced initial results of its Pilot Study of the BioLexa Platform's application on diabetic skin ulcers. This pilot study was designed to establish foundational protocols for assessing effectiveness of a therapeutic compound developed by Hoth Therapeutics, the BioLexa Platform, for accelerating and improving wound healing in the context of acute and chronic diabetic ulcers, using an animal model of impaired wound healing developed at Massachusetts General Hospital, or MGH. Upon removal of the wound dressings and the obscuring cream, Ruxandra Sirbulescu, who designed and conducted the pilot study at MGH, observed that the majority of the wounds, treated with either BioLexa or the carrier base control of BioLexa, were fully closed and re-epithelialized. While the present pilot study did not include wounds treated with saline solution, previous studies in this model have shown that wounds treated with control solutions, such as saline, remain fully open ulcers at 22 days post injury. These preliminary data suggest a benefit of BioLexa treatment over placebo in certain categories. However, a larger, well-controlled study is required before any clear conclusion can be drawn on treatment efficacy.